The Largest Congress Worldwide on Ion Therapy in HeidelbergOctober 27, 2009International experts discussed scientific and clinical development of the innovative radiation therapy The largest congress worldwide on the topic of particle or ion therapy - radiation with heavy ions and protons - has taken place in the fall of 2009 in Heidelberg. Well over 600 international participants, especially from Japan and the USA, convened in the Heidelberg Town Hall for the annual meeting of the "Particle Therapy Cooperative Group" (PTCOG), including leading experts from the fields of radiation therapy, medical physics and oncology. "There have been significant advances in the technology and clinical application of ion radiation in recent years," explained Professor Dr. Dr. Jürgen Debus, Congress Chairman and Medical Director of the Department of Radiooncology and Radiation Therapy at the Heidelberg University Hospital. "The international meeting gives us the opportunity to discuss experiences and results with colleagues and representatives of the industry and to exchange notes." So far, 70,000 patients worldwide have been treated with ions At this year's PTCOG, innovations in the field of ion therapy and its integration into already established multi-modal clinical concepts were discussed in the historic atmosphere of the Heidelberg Town Hall. The first combined facility in the world for protons and heavy ions, the Heidelberg Ion Radiation Therapy Center (HIT), which will be opened on the 2nd of November 2009 and is directly affiliated with the Heidelberg University Hospital for Radiooncology and Radiation Therapy, has the first heavy ion gantry in the world, weighing 650 tons. This represents a unique scientific basis for the meeting. PTCOG is a consortium of preclinical centers active in foundational research and clinical work in the field of particle therapy. In the course of clinical implementation, radiation therapists have also joined. Essential preliminary work for therapeutic application has been completed, especially in Berkeley, California, and at the GSI Helmholtz Center for Heavy Ion Research in Darmstadt, Germany. So far, more than 70,000 patients all over the world have been treated with ion radiation, most of them with protons and heavy ions. Ion radiation has a high biological effectiveness Heavy ions (carbon ions) differ from conventional photon radiation therapy and proton therapy by an increased relative biological effectiveness (RBE), which has shown critical therapeutic advantages, especially for slow-growing and radiation-resistant tumors. Since 1997 far more than 400 patients have been treated by the Heidelberg radiooncologists with carbon ions in cooperation with the GSI Helmholtz Center for Heavy Ion Research in Darmstadt and the Department of Medical Physics at the German Cancer Research Center (DKFZ) in Heidelberg, as well as the Rossendorf Research Center in Dresden. Therapeutic results have been significantly improved, especially for tumors at the base of the skull. Heidelberg Ion Radiation Therapy Center (HIT) will open in the fall Based on this preliminary work, the Heidelberg Ion Radiation Therapy Center (HIT) has been set up at the Heidelberg University Hospital and will soon begin clinical operation. There, it will be possible to treat more than 1,300 patients per year with ion radiation, especially those with tumors of the base of the skull such as chordomas, chondrosarcomas and meningiomas as well as tumors of the salivary glands and prostate carcinomas. Brain tumors such as glioblastomas and low-grade astrocytomas will also be treated in the context of clinical studies at the HIT. Heidelberg University Hospital |
|||||||||||||||||||||
| Related Radiation Therapy Current Events and Radiation Therapy News Articles Iowa State engineers develop 3-D software to give doctors, students a view inside the body James Oliver picked up an Xbox game controller, looked up to a video screen and used the device's buttons and joystick to fly through a patient's chest cavity for an up-close look at the bottom of the heart. Men leave: Separation and divorce far more common when the wife is the patient A woman is six times more likely to be separated or divorced soon after a diagnosis of cancer or multiple sclerosis than if a man in the relationship is the patient, according to a study that examined the role gender played in so-called "partner abandonment." The study also found that the longer the marriage the more likely it would remain intact. PET imaging response a prognostic factor after thoracic radiation therapy for lung cancer A rapid decline in metabolic activity on a PET scan after radiation therapy for non-small cell lung cancer is correlated with good local tumor control, according to a study presented by researchers at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting. Chemo-radiation before prostate removal may prevent cancer recurrence Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival. Radiation therapy technique successfully treats pain in patients with advanced cancer Stereotactic radiosurgery (SRS), a radiation therapy procedure pioneered at the University of Pittsburgh Cancer Institute (UPCI) that precisely delivers a large dose of radiation to tumors, effectively controls pain in patients with cancer that has spread to the spine. Aiming to avoid damage to neurocognitive areas of the brain during cranial radiation Radiation oncologists at Rush University Medical Center are intent on finding ways to avoid damage to the critically important hippocampus and limbic circuit of the brain when cranial radiation is required to treat existing or potential metastatic cancers. Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer Treating limited stage small cell lung cancer(LSCL) with a combination of accelerated high-dose radiotherapy and chemotherapy has shown encouraging results. Stereotactic radiotherapy offers noninvasive, effective treatment for frail patients with early-stage lung cancer Stereotactic body radiation therapy (SBRT) should be considered a new standard of care for early-stage lung cancer treatment in patients with co-existing medical problems, according to results from a national clinical trial led by UT Southwestern Medical Center physicians. Preventative brain radiation for lung cancer patients: Benefits and risks A new study is taking a closer look at the benefits versus risks for lung cancer patients to undergo preventative brain radiation therapy as a means to stop cancer from spreading to the brain. Short-term hormone therapy and intermediate dose radiation increases survivial for early stage prostate cancer Short-term hormone therapy given prior to and during intermediate dose radiation treatment for men with early stage prostate cancer increases their chance of living longer, compared to those who receive the same radiation alone. More Radiation Therapy Current Events and Radiation Therapy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||